Author

David John Wisniewski

National Cancer InstituteORCID 0000-0002-7514-7918Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Assay:proteomics· 1

Frequent Co-Authors

George W. SledgeiD· 2 shared Stanley LipkowitziD· 2 shared Danny Wangsa· 1 shared Darawalee WangsaiD· 1 shared Diya Desai· 1 shared Donna M. Voeller· 1 shared Jake MunchiD· 1 shared Jung-Min Lee· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

George W. SledgeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 19, 2026

Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancers

David John Wisniewski, Rachel K Pritz, Jake Munch…·Stanley Lipkowitz

This study shows that reducing Flotillin-2 increases T-DM1 internalization and cytotoxicity in HER2-amplified cancers by enhancing HER2 ubiquitination and internalization.

DOI 10.64898/2026.05.15.725439

humanproteomics

Cancer BiologyOncogenePeer-reviewedNov 25, 2025

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

David John Wisniewski, Donna M. Voeller, Yonit A. Addissie…·Stanley Lipkowitz

6 citations

humanbulk RNA-seq